$695 | Single User
$3475 | Site License
$10425 | Global License

Generic Defence Strategies: Targeting Patient Co-Pay
[Lowest Price Guaranteed: $695]

Published by FirstWord Pharma: 01 Mar 2012 | 10 | In Stock
Related Topics: Business , Consumer , FDA , Pharmacy , Pricing , Services

Introduction

Introduction


Coupons for co-pays are fast becoming a standard part of the brand marketer’s toolkit, due to proven positive ROI. It’s projected that by 2017, coupons will be associated with 30% of all U.S. prescriptions.


In addition to the impact on market share, advocates of “couponing” tout the benefits of making medications more affordable to patients, enabling them to receive and adhere to the most effective drug, not the cheapest.


However, the tidal wave of coupons is meeting increasing resistance from payers, who argue that when patients request non-preferred brands, healthcare costs simply rise in other areas, leaving the patient no better off


With strong opinions on both sides, what are the facts today, and how will the situation continue to unfold?


Scope


Report Overview


Generic Defence Strategies: Targeting Patient Co-Pay report gathers current perspectives from experts, to present the latest evidence on both sides of the debate. This timely FirstWord Dossier report presents recent pharma case studies, and provides a detailed review of current distribution practices, showing the successes, and challenges, of coupon programmes.


After bringing you up to speed with the latest coupon trends, this comprehensive report provides details of many ways that payers are fighting back against the practice. How can Pharma respond to this changing environment and turn a challenge into an opportunity? For future predictions and practical advice, look no further than this essential report.


Highlights


Key Report Features


  • Recent trends and key drivers in the growth of co-pay coupons

  • Goals of coupon programmes

  • Recent Pharma case studies, presenting specific tactics and results

  • Industry data on coupon response rates and overall ROI

  • Effects of couponing on consumer perceptions and behaviour

  • Coupon distribution channels and restrictions

  • Health plan and pharmacy benefit manager (PBM) reactions

  • Latest data on the impact of coupons on healthcare costs

  • Ways that payers are fighting back against coupons

  • Future predictions, insights, and recommendations

  • Puchase Reasons


    Who Would Benefit From This Report?


    This report will be of value to senior pharma directors and managers with responsibilities in the following areas:


  • Marketing, brand and sales management

  • Patient adherence

  • Pricing and reimbursement

  • Consumer marketing solutions

  • Advertising and promotion

  • Business development

  • CRM and relationship marketing

  • Multi-channel marketing

  • Strategic brand planning solutions

  • Forecasting and marketing professionals

  • This report will also benefit managed care professionals, pharmacy benefit managers, state and national legislators and health policy researchers.


    Key Questions Answered


  • Why are drug companies using coupon programmes?

  • How effective are co-pay coupons in growing market share?

  • Who is issuing coupons, and how are they reaching consumers?

  • What restrictions are there on coupon distribution, for example, in Massachusetts?

  • Why and how are payers and consumer advocacy groups pushing back on coupons?

  • What new limitations can be expected from the FDA?

  • How can Pharma and Managed Care work together to distribute coupons that meet the needs of patients and reduce costs?

  • Key Benefits


  • Get up to speed with the pharma industry’s current coupon practices

  • Through recent case studies, assess the effectiveness of coupon programmes

  • Understand distribution channels and challenges

  • Gain insight into why Managed Care, PBMs, and consumer groups are increasingly pushing back on coupons

  • Find out how formulary restrictions and other tactics are making coupons less effective

  • Receive recommendations for ways that co-pay coupon programmes can be adapted to be effective in the future


  • Key quotes


    “Coupons and vouchers provide an important benefit to patients by defraying the cost of out-of-pocket payments, breaking down barriers to access and encouraging better medication adherence.” – Karl Uhlendorf, vice president, Pharmaceutical Research and Manufacturers of America (PhRMA)


    “We do not subscribe to the theory that the use of coupons encourages patients to use more expensive drugs,” he said. “We do believe that pharmaceutical companies use coupons to increase adherence, which is in the best interest of everyone to do so.” – Todd Brown MHP, RPh, executive director, Massachusetts Independent Pharmacists Association


    “They do not reduce the cost of the drug itself and lead to increased drug costs for most employers. This cost shift ultimately adds to the overall cost of health care, which we all pay for.” – Walt Cherniak, spokesperson for Aetna


    Expert Views


  • Lori McLaughlin, corporate spokesperson, WellPoint, Inc

  • Walt Cherniak, spokesperson, Aetna

  • Brian Rosman, research director, HCFA

  • Helen Sherman, PharmD, chief pharmacy officer, RegenceRx

  • Alyssa Vangeli, policy analyst, HCFA

  • Charles K. Brown, vice president of marketing, NCH Marketing Services

  • Matthew Perri, PhD., professor of clinical and administrative pharmacy, University of Georgia College of Pharmacy

  • Marv Shepherd, Ph.D., director of the Center for Pharmacoeconomic Studies, University of Texas, Austin

  • Todd Brown MHP, RPh, executive director, Massachusetts Independent Pharmacists Association

  • Charles Coté, assistant vice president, strategic communications, Pharmaceutical Care Management Association
  • Table of Contents
    for Generic Defence Strategies: Targeting Patient Co-Pay

    • 1.Introduction

      2.Formulary management

      3.Co-payment coupons: Numerous goals

      3.1 Case study

      3 2 Coupons common, growing

      4.High redemption rate

      4.1. Coupons affect consumer perception

      4.2. PhRMA: Coupons increase adherence

      3.Coupon distribution

      3.1. Coupon programmes target manufacturers

      3.2. Coupons banned in federal programmes, and Massachusetts

      3.3. Opposing Massachusetts ban

      3.4.Health plan and PBM reaction: Higher costs, safety concerns

      3.5. Hidden from PBM/health plan sight

      3.6. PCMA report: billion in excess costs

      4.Payers fight back

      4.1. Consumer advocates push back

      4.2.Looking to the future

      4.3. FDA to study issue

      5.Acknowledgements

    Additional Details

    Publisher

    FirstWord Pharma

    Publisher Information

    Reference

    10 |

    Number of Pages

    41

    Report Format

    PDF

    FirstWord Pharma Reports

    Related Reports

    TitleDate PublishedPrice fromMore Details
    Generic Health Pty, Ltd. – Mergers & Acquisitions (M&A), Partnerships & Alliances and Investment Report
    SummaryMarketLine's Company Mergers & Acquisitions (M&A), Partnerships & Alliances and Investments r...
    15 Apr 2016 by Marketline USD $350 More Info
    JP Giants leaning in for becoming a Speciality Global Pharma Sakigake designation – A Push from government to “Innovate”! “Essential drugs” exemption from Z2 rule- Balancing long listed pricing pressure! Authorized Generics, Biosimilars, and Patent Litigations - Avenues to grow in JP Generic market!
    Sakigake designation – A Push from government to “Innovate”!“Essential drugs” exemption from Z2 rule...
    10 Mar 2016 by MP Advisors USD $2,500 More Info
    Active Pharmaceutical Ingredient Market by type (Innovative, Generic), Type of Synthesis (Synthetic, Biotech), Type of Manufacturer (Captive, Merchant), Therapy (Oncology, diabetes, Orthopedic, CNS, Nephrology, Ophthalmology) - Global Forecast to 2020
    The Active Pharmaceutical Ingredients market is categorized on the basis of type, type of manufactur...
    28 Oct 2015 by MarketsandMarkets USD $5,650 More Info
    Indian Generic Drug Market Outlook 2020
    Generics drugs are bioequivalent versions of the originator medicines. These drugs are cheaper and o...
    01 Sep 2015 by RNCOS USD $800 More Info
    Life Cycle Management Strategies - Optimizing revenues and defending generic competition
    Life Cycle Management Strategies - Optimizing revenues and defending generic competitionSummaryGBI R...
    02 Jul 2015 by CBR Pharma Insights USD $2,995 More Info
    Physician Views: Can Lundbeck and Otsuka's newly approved Rexulti compete with branded and generic competition in the schizophrenia and depression markets?
    ScopeFDA approval of Lundbeck and Otsuka Pharmaceuticals' Rexulti – which was announced last week – ...
    01 Jul 2015 by FirstWord Pharma USD $695 More Info
    US Generic Drug Market Outlook 2018
    The US is the largest pharmaceutical market in the world. Driven by the factors such as large health...
    01 Feb 2015 by RNCOS USD $1,200 More Info
    Physician Views: How will neurologists embrace Teva's new version of Copaxone? What about potential generic versions later this year?
    Scope The US multiple sclerosis market is expected to evolve notably in 2014, with analysts now conf...
    05 Feb 2014 by FirstWord Pharma USD $695 More Info
    Physician Views: The great generic Advair opportunity – a physician perspective
    ScopeAs illustrated here – see FirstWord Lists: Leading respiratory drugs 2012 and 2018 – the respir...
    01 Oct 2013 by FirstWord Pharma USD $695 More Info
    Physician Views: Will generic Copaxone have traction in the MS market given emergence of oral therapies?
    ScopeA recent ruling by the US Court of Appeals for the Federal Circuit has increased the likelihood...
    01 Aug 2013 by FirstWord Pharma USD $695 More Info

    This report is published by FirstWord Pharma

    Download Free Report Summary PDF

    Generic Defence Strategies: Targeting Patient Co-Pay | Download PDF Summary

    Download our FREE report summary PDF. It contains all the information on these web pages, plus a Proforma Invoice request form, should you need it to satisfy your company's internal order procedures.

    Ordering Information

    Orders are processed immediately and you will be notified of the despatch date on confirmation of your order.

    Accepted Card Types

    Payment

    Buy now using our secure payment system.

    We Stock...